Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

894.85 +2.37 (+0.27%)
Streaming Delayed Price Updated: 10:45 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters
Though tech innovators blossomed this year, you can still find undervalued deals. 
Via InvestorPlace
$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
Via Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
Via Benzinga
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
You can pick these players up for a great price right now. 
Via The Motley Fool
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
11 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN).
Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics. 
Via Chartmill
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Regeneron has been an excellent investment in recent years. Can that trend continue? 
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
2 Soaring Stocks to Buy and Hold
Both of these companies crushed earnings season. 
Via The Motley Fool
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than- 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.